CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
复制标题
DOI:
10.1016/j.celrep.2016.05.058
复制
发表时间:
2016-06-21
期刊:
影响因子:
8.8
通讯作者:
Vonderheide RH
中科院分区:
文献类型:
--
作者:
Byrne KT;Vonderheide RH
Cancer immunotherapies are more effective in tumors with robust T cell infiltrates, but mechanisms to convert T cell-devoid tumors with active immunosuppression to those capable of recruiting T cells remain incompletely understood. Here, using genetically engineered mouse models of pancreatic ductal adenocarcinoma (PDA), we demonstrate that a single dose of agonistic CD40 antibody with chemotherapy rendered PDA susceptible to T cell-dependent destruction and potentiated durable remissions. CD40 stimulation caused a clonal expansion of T cells in the tumor, but the addition of chemotherapy optimized myeloid activation and T cell function. Although recent data highlights the requirement for innate sensors in cancer immunity, these canonical pathways – including TLRs, inflammasome, and Type I interferon/STING – played no role in mediating the efficacy of CD40/chemotherapy. Thus, CD40 functions as a non-redundant mechanism to convert the tumor microenvironment immunologically. Our data provide a rationale for a newly initiated clinical trial of CD40/chemotherapy in PDA. Immunologically ‘cold’ tumors lack T cells and are hyporesponsive to immunotherapies. Byrne and Vonderheide show that CD40 stimulation, with chemotherapy, converts a ‘cold’ tumor to a site of T cell infiltration and destruction, with durable responses. Functional immune responses are independent of innate immune sensors important in other settings.